Öz
Multiple sclerosis (MS) is currently incurable, although a variety of treatment approaches are available, including physiotherapy, psychotherapy, and management strategies to mitigate the symptoms of MS. However, immunomodulatory agents are available that can modify the course of the disease by altering the pathological immune responses underlying MS. Treatment with these disease-modifying drugs (DMDs) aims to reduce the rate of acute neurological attacks, and can delay disability progression. Nurses play an effective and active role in patients with multiple sclerosis (MS) for the managing the treatment regimen, education and follow-up for the disease. Nurses who giving one-to-one care to patients, have important responsibilities to understand the effects of disease modifying therapies (DMT) therapies that lead to changes in the prognosis of MS. Because DMT treatments can last throughout life, doctor, nurse and MS patient should be compatible. Patient adherence is very important in the treatment of MS and it is an important goal to ensure that the patient is fully benefited from treatment to improve adherence. It is important for nurses to know the effects and side effects of DMT and to understand the needs of MS patients in order to encourage the adherence of treatment to MS patients. In this review, it is aimed to guide the nurses about how they can help MS patients to understand the clinical effects, potential side effects, patient monitoring requirements of MS treatment options and to be able to understand these effects, and to gain knowledge about MS treatment.
Anahtar Kelimeler
Kaynakça
- 1. Higuera L, Carlin CS, Anderson S. Adherence to disease- modifying therapies for multiple sclerosis. J Manag Care Spec Pharm 2016;22(12):1394Y1401.2.
- 2. Disanto G, Berlanga AJ, Handel AE, Para AE, Burrell AM, Fries A et. al. Heterogeneity in multiple sclerosis: scratching the surface of a complex disease. Autoimmune Diseases 2011;932351:1-12.
- 3. Bandari DS, Sternaman D, Chan D, Prostko CR, Sapir T. Evaluating risks, costs, and benefits of new and emerging therapies to optimize outcomes in multiple sclerosis. Journal of Managed Care and Specialty Pharmacy 2012;18(9):1–17.
- 4. Wiese MD, Suppiah V, O'Doherty C. Metabolic and safety issues for multiple sclerosis pharmacotherapy--opportunities for personalised medicine. Expert Opin Drug Metab Toxicol 2014;10(8):1145-1159.
- 5. Morgante L, Lowden D, Larocca T. Decision making in multiple sclerosis: theory to practice. International Journal of MS Care 2006;8(4):113-120.
- 6. Heesen C, Köpke S, Richter T, Kasper J. Shared decision making and self-management in multiple sclerosis--a consequence of evidence. J Neurol 2007;254(Suppl 2):116-121.
- 7. Heesen C, Kleiter I, Meuth SG, Krämer J, Kasper J, Köpke S et. al. Benefit-risk perception of natalizumab therapy in neurologists and a large cohort of multiple sclerosis patients. J Neurol Sci 2017;15(376):181-190.
- 8. Kraetschmer N, Sharpe N, Urowitz S, Deber RB. How does trust affect patient preferences for participation in decision-making?. Health Expect 2004;7(4):317-326.
- 9. Burke T, Dishon S, McEwan L, Smrtka J. The evolving role of the multiple sclerosis nurse: an ınternational perspective. International Journal of MS Care 2011;13(3):105-112.
- 10. Roman C, Menning K. [Treatment and disease management of multiple sclerosis patients: A review for nurse practitioners. J Am Assoc Nurse Pract 2017;29(10):629-638.
- 11. Lublin FD, Reingold SC, Cohen JA, Cutter GR, Sørensen PS, Thompson AJ et. al. Defining the clinical course of multiple sclerosis: the 2013 revisions. Neurology 2014;83(3):278-286.
- 12. Tremlett H, Yinshan Zhao, Devonshire V. Natural history of secondary-progressive multiple sclerosis. Mult Scler 2008;14(3):314-324.
- 13. Kaunzner UW, Kumar G, Askin G, Gauthier SA, Nealon NN, Vartanian T et. al. A study of patients with aggressive multiple sclerosis at disease onset. Neuropsychiatr Dis Treat 2016;12:1907-1912.
- 14. Ziemssen T, De Stefano N, Sormani MP, Van Wijmeersch B, Wiendl H, Kieseier BC. Optimizing therapy early in multiple sclerosis: An evidence-based view. Mult Scler Relat Disord 2015;4(5):460-469.
- 15. Devonshire V, Lapierre Y, Macdonell R, Ramo-Tello C, Patti F, Fontoura P et. al. The Global Adherence Project (GAP): a multicenter observational study on adherence to disease-modifying therapies in patients with relapsing-remitting multiple sclerosis. Eur J Neurol 2011;18(1):69-77.
- 16. Kappos L, Freedman MS, Polman CH, Edan G, Hartung HP, Miller DH et. al. Effect of early versus delayed interferon beta-1b treatment on disability after a first clinical event suggestive of multiple sclerosis: a 3-year follow-up analysis of the BENEFIT study. Lancet 2007;370(9585):389-397.
- 17. Revel M. Interferon-beta in the treatment of relapsing-remitting multiple sclerosis. Pharmacol Ther 2003;100(1):49-62.
- 18. Comi G, Martinelli V, Rodegher M, Moiola L, Bajenaru O, Carra A et. al. Effect of glatiramer acetate on conversion to clinically definite multiple sclerosis in patients with clinically isolated syndrome (PreCISe study): a randomised, double-blind, placebo-controlled trial. Lancet 2009;374(9700):1503-1511.
- 19. Embrey N. Multiple sclerosis: managing a complex neurological disease. Nurs Stand 2014;29(11):49-58.
- 20. Portaccio E, Zipoli V, Siracusa G, Sorbi S, Amato MP. Long-term adherence to interferon beta therapy in relapsing-remitting multiple sclerosis. Eur Neurol 2008;59(3-4):131-135.
- 21. Treadaway K, Cutter G, Salter A, Lynch S, Simsarian J, Corboy J et. al. Factors that influence adherence with disease-modifying therapy in MS. J Neurol 2009;256(4):568-576.
- 22. Hansen K, Schüssel K, Kieble M, Werning J, Schulz M, Friis R, Pöhlau D et. al. Adherence to Disease Modifying Drugs among Patients with Multiple Sclerosis in Germany: A Retrospective Cohort Study. PLoS One 2015;10(7):e0133279.
- 23. McKay KA, Tremlett H, Patten SB, Fisk JD, Evans C, Fiest K et. al. Determinants of non-adherence to disease-modifying therapies in multiple sclerosis: A cross-Canada prospective study. Mult Scler 2017;23(4):588-596.
- 24. Erbay Ö, Usta Yeşilbalkan Ö, Yüceyar N. Factors affecting the adherence to disease-modifying therapy in patients with multiple sclerosis. J Neurosci Nurs 2018;50(5):291-297.
- 25. Kołtuniuk A, Rosińczuk J. Adherence to disease-modifying therapies in patients with multiple sclerosis. Patient Prefer Adherence 2018;12:1557-1566.
- 26. Ožura A, Kovač L, Sega S. Adherence to disease-modifying therapies and attitudes regarding disease in patients with multiple sclerosis. Clin Neurol Neurosurg 2013;115(Suppl 1):S6-11.
- 27. Di Battista G, Bertolotto A, Gasperini C, Ghezzi A, Maimone D, Solaro C. Multiple sclerosis state of the art (SMART): A qualitative and quantitative analysis of therapy's adherence, hospital reliability's perception, and services provided quality. Mult Scler Int 2014;2014:752318.
- 28. Costello K, Sipe JC. Cladribine tablets' potential in multiple: sclerosis treatment. J Neurosci Nurs 2008;40(5):275-280.
- 29. Kappos L, Radue EW, O'Connor P, Polman C, Hohlfeld R, Calabresi P et. al. A placebo-controlled trial of oral fingolimod in relapsing multiple sclerosis. N Engl J Med 2010;362(5):387-401.
- 30 Kappos L, Li D, Calabresi PA, O'Connor P, Bar-Or A, Barkhof F et. al. Ocrelizumab in relapsing-remitting multiple sclerosis: a phase 2, randomised, placebo-controlled, multicentre trial. Lancet 2011;378(9805):1779-1787.
- 31. Bittner S, Wiendl H. Neuroimmunotherapies targeting t cells: from pathophysiology to therapeutic applications. Neurotherapeutics 2016;13(1):4-19.
- 32. Mulero P, Midaglia L, Montalban X. Ocrelizumab: a new milestone in multiple sclerosis therapy. Ther Adv Neurol Disord 2018;11:1756286418773025.
- 33. Singer BA. The role of natalizumab in the treatment of multiple sclerosis: benefits and risks. Ther Adv Neurol Disord 2017;10(9):327-336.
- 34. Remington G, Rodriguez Y, Logan D, Williamson C, Treadaway K. Facilitating medication adherence in patients with multiple sclerosis. Int J MS Care 2013;15(1):36-45.
- 35. Wilson L, Loucks A, Bui C, Gipson G, Zhong L, Schwartzburg A et al. Patient centered decision making: use of conjoint analysis to determine risk-benefit trade-offs for preference sensitive treatment choices. J Neurol Sci 2014;344(1-2):80-87.
- 36. Subei AM, Ontaneda D. Risk mitigation strategies for adverse reactions associated with the disease-modifying drugs in multiple sclerosis. CNS Drugs 2015;29(9):759-771.
- 37. Krueger JG, Kircik L, Hougeir F, Friedman A, You X, Lucas N et. al. Cutaneous adverse events in the randomized, double-blind, active-comparator DECIDE study of daclizumab high-yield process versus ıntramuscular ınterferon beta-1a in relapsing-remitting multiple sclerosis. Adv Ther 2016;33(7):1231-1245.
- 38. Clanet MC, Wolinsky JS, Ashton RJ, Hartung HP, Reingold SC. Risk evaluation and monitoring in multiple sclerosis therapeutics. Mult Scler 2014;20(10):1306-1311.
Öz
Multipl
skleroz (MS) hastalığı, çeşitli tedavi yaklaşımlarına (fizyoterapi, psikoterapi
ve yönetim stratejileri) rağmen kesin tedavisi mümkün olmayan bir hastalıktır.
Ancak hastalığın altında yatan patolojik bağışıklık tepkilerini değiştiren
mevcut immünomodülatörler bu hastalığın gidişatını etkileyebilmektedir. Bu
hastalık için kullanılan, hastalığı modifiye edici ilaçlar [disease modifying
therapies (DMT)] akut nörolojik atakların oranını azaltmakta ve özürlülüğün
ilerlemesini geciktirebilmektedir. Multipl sklerozlu hastaların tedavi rejimi
ve hastalığa yönelik eğitim ve izlemde bu alanda çalışan hemşireler etkin ve
aktif bir rol oynamaktadır. Hastalığın prognozunda değişikliklere yol açan
hastalık modifiye edici tedavilerin etkilerini anlamak, hastalara birebir bakım
veren hemşirelerin önemli sorumluluklarındandır. Multipl skleroza yönelik bu
tedavilerinin yaşam boyunca sürebilmesi nedeniyle hekim ile birlikte hemşirenin
de MS hastasıyla uyumlu çalışması önemlidir. Hastalığın tedavisinde uyum çok
önemlidir ve tedaviye uyumu artırmak için hastanın tedaviden tam yarar
görmesini sağlamak önemli bir hedeftir. Hasta eğitiminde hastanın durumu,
uygulanması gereken tedavi ve tedavi yararlarının tartışılması bu hedefe
ulaşılmasında büyük önem taşımaktadır. Hemşirelerin, MS hastalarının tedaviye
uyumunu teşvik etmesi için DMT etki ve yan etkilerini bilmesi, MS hastasının
gereksinimlerini anlaması önemlidir.
Bu
derlemede mevcut MS tedavi seçeneklerinin oluşturabileceği klinik etkiler,
potansiyel yan etkiler, hasta izleme gereksinimleri ve hastaların bu etkileri
anlamasına nasıl yardımcı olacakları konusunda hemşirelere rehberlik etmek ve
MS tedavisine yönelik bilgi kazandırmak amaçlanmıştır.
Anahtar Kelimeler
Multipl skleroz hemşirelik yönetimi hastalık modifiye edici tedavi
Kaynakça
- 1. Higuera L, Carlin CS, Anderson S. Adherence to disease- modifying therapies for multiple sclerosis. J Manag Care Spec Pharm 2016;22(12):1394Y1401.2.
- 2. Disanto G, Berlanga AJ, Handel AE, Para AE, Burrell AM, Fries A et. al. Heterogeneity in multiple sclerosis: scratching the surface of a complex disease. Autoimmune Diseases 2011;932351:1-12.
- 3. Bandari DS, Sternaman D, Chan D, Prostko CR, Sapir T. Evaluating risks, costs, and benefits of new and emerging therapies to optimize outcomes in multiple sclerosis. Journal of Managed Care and Specialty Pharmacy 2012;18(9):1–17.
- 4. Wiese MD, Suppiah V, O'Doherty C. Metabolic and safety issues for multiple sclerosis pharmacotherapy--opportunities for personalised medicine. Expert Opin Drug Metab Toxicol 2014;10(8):1145-1159.
- 5. Morgante L, Lowden D, Larocca T. Decision making in multiple sclerosis: theory to practice. International Journal of MS Care 2006;8(4):113-120.
- 6. Heesen C, Köpke S, Richter T, Kasper J. Shared decision making and self-management in multiple sclerosis--a consequence of evidence. J Neurol 2007;254(Suppl 2):116-121.
- 7. Heesen C, Kleiter I, Meuth SG, Krämer J, Kasper J, Köpke S et. al. Benefit-risk perception of natalizumab therapy in neurologists and a large cohort of multiple sclerosis patients. J Neurol Sci 2017;15(376):181-190.
- 8. Kraetschmer N, Sharpe N, Urowitz S, Deber RB. How does trust affect patient preferences for participation in decision-making?. Health Expect 2004;7(4):317-326.
- 9. Burke T, Dishon S, McEwan L, Smrtka J. The evolving role of the multiple sclerosis nurse: an ınternational perspective. International Journal of MS Care 2011;13(3):105-112.
- 10. Roman C, Menning K. [Treatment and disease management of multiple sclerosis patients: A review for nurse practitioners. J Am Assoc Nurse Pract 2017;29(10):629-638.
- 11. Lublin FD, Reingold SC, Cohen JA, Cutter GR, Sørensen PS, Thompson AJ et. al. Defining the clinical course of multiple sclerosis: the 2013 revisions. Neurology 2014;83(3):278-286.
- 12. Tremlett H, Yinshan Zhao, Devonshire V. Natural history of secondary-progressive multiple sclerosis. Mult Scler 2008;14(3):314-324.
- 13. Kaunzner UW, Kumar G, Askin G, Gauthier SA, Nealon NN, Vartanian T et. al. A study of patients with aggressive multiple sclerosis at disease onset. Neuropsychiatr Dis Treat 2016;12:1907-1912.
- 14. Ziemssen T, De Stefano N, Sormani MP, Van Wijmeersch B, Wiendl H, Kieseier BC. Optimizing therapy early in multiple sclerosis: An evidence-based view. Mult Scler Relat Disord 2015;4(5):460-469.
- 15. Devonshire V, Lapierre Y, Macdonell R, Ramo-Tello C, Patti F, Fontoura P et. al. The Global Adherence Project (GAP): a multicenter observational study on adherence to disease-modifying therapies in patients with relapsing-remitting multiple sclerosis. Eur J Neurol 2011;18(1):69-77.
- 16. Kappos L, Freedman MS, Polman CH, Edan G, Hartung HP, Miller DH et. al. Effect of early versus delayed interferon beta-1b treatment on disability after a first clinical event suggestive of multiple sclerosis: a 3-year follow-up analysis of the BENEFIT study. Lancet 2007;370(9585):389-397.
- 17. Revel M. Interferon-beta in the treatment of relapsing-remitting multiple sclerosis. Pharmacol Ther 2003;100(1):49-62.
- 18. Comi G, Martinelli V, Rodegher M, Moiola L, Bajenaru O, Carra A et. al. Effect of glatiramer acetate on conversion to clinically definite multiple sclerosis in patients with clinically isolated syndrome (PreCISe study): a randomised, double-blind, placebo-controlled trial. Lancet 2009;374(9700):1503-1511.
- 19. Embrey N. Multiple sclerosis: managing a complex neurological disease. Nurs Stand 2014;29(11):49-58.
- 20. Portaccio E, Zipoli V, Siracusa G, Sorbi S, Amato MP. Long-term adherence to interferon beta therapy in relapsing-remitting multiple sclerosis. Eur Neurol 2008;59(3-4):131-135.
- 21. Treadaway K, Cutter G, Salter A, Lynch S, Simsarian J, Corboy J et. al. Factors that influence adherence with disease-modifying therapy in MS. J Neurol 2009;256(4):568-576.
- 22. Hansen K, Schüssel K, Kieble M, Werning J, Schulz M, Friis R, Pöhlau D et. al. Adherence to Disease Modifying Drugs among Patients with Multiple Sclerosis in Germany: A Retrospective Cohort Study. PLoS One 2015;10(7):e0133279.
- 23. McKay KA, Tremlett H, Patten SB, Fisk JD, Evans C, Fiest K et. al. Determinants of non-adherence to disease-modifying therapies in multiple sclerosis: A cross-Canada prospective study. Mult Scler 2017;23(4):588-596.
- 24. Erbay Ö, Usta Yeşilbalkan Ö, Yüceyar N. Factors affecting the adherence to disease-modifying therapy in patients with multiple sclerosis. J Neurosci Nurs 2018;50(5):291-297.
- 25. Kołtuniuk A, Rosińczuk J. Adherence to disease-modifying therapies in patients with multiple sclerosis. Patient Prefer Adherence 2018;12:1557-1566.
- 26. Ožura A, Kovač L, Sega S. Adherence to disease-modifying therapies and attitudes regarding disease in patients with multiple sclerosis. Clin Neurol Neurosurg 2013;115(Suppl 1):S6-11.
- 27. Di Battista G, Bertolotto A, Gasperini C, Ghezzi A, Maimone D, Solaro C. Multiple sclerosis state of the art (SMART): A qualitative and quantitative analysis of therapy's adherence, hospital reliability's perception, and services provided quality. Mult Scler Int 2014;2014:752318.
- 28. Costello K, Sipe JC. Cladribine tablets' potential in multiple: sclerosis treatment. J Neurosci Nurs 2008;40(5):275-280.
- 29. Kappos L, Radue EW, O'Connor P, Polman C, Hohlfeld R, Calabresi P et. al. A placebo-controlled trial of oral fingolimod in relapsing multiple sclerosis. N Engl J Med 2010;362(5):387-401.
- 30 Kappos L, Li D, Calabresi PA, O'Connor P, Bar-Or A, Barkhof F et. al. Ocrelizumab in relapsing-remitting multiple sclerosis: a phase 2, randomised, placebo-controlled, multicentre trial. Lancet 2011;378(9805):1779-1787.
- 31. Bittner S, Wiendl H. Neuroimmunotherapies targeting t cells: from pathophysiology to therapeutic applications. Neurotherapeutics 2016;13(1):4-19.
- 32. Mulero P, Midaglia L, Montalban X. Ocrelizumab: a new milestone in multiple sclerosis therapy. Ther Adv Neurol Disord 2018;11:1756286418773025.
- 33. Singer BA. The role of natalizumab in the treatment of multiple sclerosis: benefits and risks. Ther Adv Neurol Disord 2017;10(9):327-336.
- 34. Remington G, Rodriguez Y, Logan D, Williamson C, Treadaway K. Facilitating medication adherence in patients with multiple sclerosis. Int J MS Care 2013;15(1):36-45.
- 35. Wilson L, Loucks A, Bui C, Gipson G, Zhong L, Schwartzburg A et al. Patient centered decision making: use of conjoint analysis to determine risk-benefit trade-offs for preference sensitive treatment choices. J Neurol Sci 2014;344(1-2):80-87.
- 36. Subei AM, Ontaneda D. Risk mitigation strategies for adverse reactions associated with the disease-modifying drugs in multiple sclerosis. CNS Drugs 2015;29(9):759-771.
- 37. Krueger JG, Kircik L, Hougeir F, Friedman A, You X, Lucas N et. al. Cutaneous adverse events in the randomized, double-blind, active-comparator DECIDE study of daclizumab high-yield process versus ıntramuscular ınterferon beta-1a in relapsing-remitting multiple sclerosis. Adv Ther 2016;33(7):1231-1245.
- 38. Clanet MC, Wolinsky JS, Ashton RJ, Hartung HP, Reingold SC. Risk evaluation and monitoring in multiple sclerosis therapeutics. Mult Scler 2014;20(10):1306-1311.
Ayrıntılar
| Birincil Dil | Türkçe |
|---|---|
| Konular | Hemşirelik |
| Bölüm | Derleme |
| Yazarlar | |
| Yayımlanma Tarihi | 15 Ocak 2020 |
| Yayımlandığı Sayı | Yıl 2020 Cilt: 13 Sayı: 1 |
Dokuz Eylül Üniversitesi Hemşirelik Fakültesi Elektronik Dergisi ULAKBİM Türk Tıp Dizini, Türk Medline, Türkiye Atıf Dizini, Şubat 2021 tarihinden beri EBSCO Host ve 26 Ekim 2021 tarihinden itibaren DOAJ ve 18 Ocak 2022 tarihinden beri Index Copernicus tarafından indekslenmektedir.
